Update from Lexeo Therapeutics
In a press release today, June 15, 2026, Lexeo Therapeutics announced that the Company has finalized the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan (SAP) intended to provide clinical evidence to support the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for gene therapy candidate LX2006 under the accelerated approval pathway in 2028.
Learn more about Lexeo Therapeutics’ LX2006 Gene Therapy program on our pipeline page.